Stereotactic Re-Irradiation for Local Recurrence after Radical Prostatectomy and Radiation Therapy: A Retrospective Multicenter Study.

prostate cancer re-irradiation stereotactic body radiation therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 Aug 2021
Historique:
received: 19 07 2021
revised: 20 08 2021
accepted: 23 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 11 9 2021
Statut: epublish

Résumé

Prostate cancer recurrence in patients previously treated with radical prostatectomy and radiation therapy is challenging. Re-irradiation could be an option, but data regarding efficacy and safety are lacking. We retrospectively evaluated salvage re-irradiation for local recurrence after prostatectomy and external beam radiation therapy. We collected data from 48 patients who underwent salvage reirradiation with stereotactic radiation therapy for local prostate cancer recurrence in the prostatic bed at four French centers. Fifteen patients (31%) were on androgen deprivation therapy during stereotactic radiotherapy. Biochemical response and relapse-free survival were analyzed, and post-treatment toxicities were assessed according to the Common Terminology of Adverse Events criteria. Five patients had grade 3 late bladder toxicity (cystitis), three had grade 3 late incontinence, and one had grade 3 late chronic pain. At three months, 83% of patients had a positive biochemical response. The median follow-up was 22 months. At the end of the follow-up, 21 patients (43%) had a biochemical relapse. The median time to biologic relapse was 27 months. The biochemical relapse rates at 1 and 2 years were 80% and 52%, respectively. In conclusion, salvage re-irradiation for recurrent prostate cancer in the prostate bed may generate significant toxicity rates, and a prospective study with appropriate patient selection is needed to evaluate its effectiveness.

Identifiants

pubmed: 34503149
pii: cancers13174339
doi: 10.3390/cancers13174339
pmc: PMC8430661
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Oncol (R Coll Radiol). 2018 Feb;30(2):93-100
pubmed: 29208480
Acta Oncol. 2012 Nov;51(8):963-74
pubmed: 22966812
Skeletal Radiol. 2019 Dec;48(12):1915-1924
pubmed: 31127357
J Urol. 2019 Sep;202(3):533-538
pubmed: 31042111
Tumori. 2015 Apr 28;101(2):e57-9
pubmed: 25721678
Eur Urol. 2021 Apr;79(4):537-544
pubmed: 33317857
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):614-621
pubmed: 30825495
JAMA. 2005 Jul 13;294(2):238-44
pubmed: 16014598
J Urol. 2000 Jul;164(1):101-5
pubmed: 10840432
Biom J. 2018 May;60(3):431-449
pubmed: 29292533
Front Oncol. 2019 Feb 15;9:71
pubmed: 30828565
Lancet Oncol. 2019 Dec;20(12):1740-1749
pubmed: 31629656
World J Urol. 2016 Mar;34(3):311-7
pubmed: 26062525
Brachytherapy. 2021 Jan-Feb;20(1):19-28
pubmed: 32798180
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Urol Clin North Am. 2001 Aug;28(3):555-65
pubmed: 11590814
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Clin Nucl Med. 2019 Dec;44(12):e629-e633
pubmed: 31689286
Br J Radiol. 2015 Aug;88(1052):20150197
pubmed: 26055506
J Clin Med. 2020 Jul 21;9(7):
pubmed: 32708097
Lancet Oncol. 2016 Jun;17(6):747-756
pubmed: 27160475
Neoplasma. 2019 Mar 5;66(2):308-314
pubmed: 30509110
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Am J Clin Exp Urol. 2014 Dec 25;2(4):286-93
pubmed: 25606574
Eur Urol. 2015 May;67(5):825-36
pubmed: 25097095
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Cancer Treat Rev. 2018 Nov;70:223-231
pubmed: 30300771
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Oncol. 2020 Oct;21(10):1341-1352
pubmed: 33002438

Auteurs

Tanguy Perennec (T)

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Boulevard J. Monod, 44800 St-Herblain, France.

Loig Vaugier (L)

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Boulevard J. Monod, 44800 St-Herblain, France.

Alain Toledano (A)

Department of Radiation Oncology, Institut de Radiothérapie et Radiochirurgie Hartmann, 92300 Levallois, France.

Nathaniel Scher (N)

Department of Radiation Oncology, Institut de Radiothérapie et Radiochirurgie Hartmann, 92300 Levallois, France.

Astrid Thomin (A)

Department of Radiation Oncology, Bretonneau Hospital, 37000 Tours, France.

Yoann Pointreau (Y)

Department of Radiation Oncology, Centre Jean Bernard-Institut Inter-RégionaL de Cancérologie (ILC), 72000 Le Mans, France.

Guillaume Janoray (G)

Department of Radiation Oncology, Bretonneau Hospital, 37000 Tours, France.

Renaud De Crevoisier (R)

Department of Radiation Oncology, Institute Eugene Marquis, 35000 Rennes, France.

Stéphane Supiot (S)

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Boulevard J. Monod, 44800 St-Herblain, France.
Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), UMR 892 Inserm-6299 CNRS, Institut de Recherche en Santé de l'Université de Nantes, 8 Quai Moncousu, BP 70721, CEDEX 1, 44007 Nantes, France.

Classifications MeSH